Acado Limited, a Caribbean joint venture, must sell the local distribution rights to one of its insulin brands by September 2026 — or lose the right to complete a landmark acquisition, according to a Fair Trading Commission (FTC) ruling released this week. The move aims to protect an estimated 250,000 Jamaicans living with diabetes, who rely on one of three insulin brands. The acquisition would reduce the number of companies selling them to a single entity.